Methods. Overall, 264 previously untreated stage II-III operable breast cancer patients were randomized to receive either standard treatment (arm A, n 5 131), consisting of fluorouracil, epirubicin, and cyclophosphamide (FEC100: 500, 100, and 500 mg/m 2 , respectively, for 3 cycles) followed by docetaxel (100 mg/m 2 for 3 cycles), or adapted treatment (arm B, n 5 133), beginning with 2 cycles of FEC100 and switching to docetaxel if tumor size decreased by ,30% after 2 cycles or ,50% after 4 cycles of FEC100 (ultrasound assessments according to World Health Organization criteria). Otherwise, FEC100 was given for six cycles before surgery. Intent-to-treat analysis was performed. Results. Similar results were observed for clinical response (objective response was 54% vs 56%, p 5 .18), breast conservation surgery (BCS; 67% vs 68%, p 5 .97), and pathological complete response rate (Chevallier classification: 14% vs 11%, p 5 .68; Statloff classification: 16% vs 13%, p 5 .82) between arms A and B. Similar toxicities were observed, even with unbalanced numbers of FEC100 and docetaxel courses. 
DISCUSSION
One of the important advantages of using neoadjuvant chemotherapy is early identification of unresponsive tumors, providing the opportunity to terminate an ineffective therapy and/or switch to an alternative systemic treatment. We wondered whether an adapted strategy would improve clinical outcome.
Our results demonstrated no significant difference between standard (arm A) and adapted (arm B) treatment based on pathological complete response (pCR) rate (primary end point) (Figs. 1, 2) did not improve the pCR rate compared with conventional treatment, at 17.7% versus 15.5%, respectively. In the subgroup analysis performed for luminal and triple-negative breast cancer (TNBC), we did not observe a significant difference in pCR rate between arms; however,TNBC achieved a higher pCR rate, with 35% versus 9% for luminal tumors (p 5 .002) in arm A and 42% versus 6% (p , .0001) in arm B, using Chevallier's classification.
Two reference regimens for early operable BC, FEC100 (fluorouracil, epirubicin, and cyclophosphamide at 500, 100, and 500 mg/m 2 , respectively, for 3 cycles) and docetaxel (100 mg/m 2 for 3 cycles), were given in standard and adapted arms, which were scheduled to receive equally 6 cycles of treatment. An imbalance in the number of FEC100 and docetaxel courses was observed because of the adapted strategy beginning with FEC100. The total numbers of FEC100 and docetaxel cycles were 375 and 364, respectively, in arm A and 478 and 262, respectively, in arm B. This did not lead to a statistically significant difference in toxicities, either nonhematological or hematological.
In conclusion, the adapted treatment had clinical results similar to those with the standard regimen in terms of clinical response, pathological response, BCS rate, and toxicities. Further disease-free and overall survival results are awaited.
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